VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q41274798  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000042.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q41274798‏
024 ‎‡a  0000-0002-7060-1675‏ ‎‡2  orcid‏
035 ‎‡a  (OCoLC)Q41274798‏
100 0 ‎‡a  Je-Hwan Lee‏ ‎‡9  sl‏
400 0 ‎‡a  Je-Hwan Lee‏ ‎‡c  researcher‏ ‎‡9  en‏
400 0 ‎‡a  Je-Hwan Lee‏ ‎‡c  wetenschapper‏ ‎‡9  nl‏
400 0 ‎‡a  Je-Hwan Lee‏ ‎‡c  investigador/a‏ ‎‡9  es‏
400 0 ‎‡a  Je-Hwan Lee‏ ‎‡c  investigador‏ ‎‡9  ast‏
670 ‎‡a  Author's A case of de novo aleukemic mast cell leukemia without c-KIT mutations in exons 8 and 17.‏
670 ‎‡a  Author's A case of refractory thrombocytopenia with 5q deletion: myelodysplastic syndrome mimicking idiopathic thrombocytopenic purpura‏
670 ‎‡a  Author's A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.‏
670 ‎‡a  Author's A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.‏
670 ‎‡a  Author's A Phase II Trial of Fludarabine/Melphalan 100 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Patients With Lymphoma‏
670 ‎‡a  Author's Androgen therapy for patients with lower-risk myelodysplastic syndrome and significant cytopenia: a retrospective study‏
670 ‎‡a  Author's Biomarkers for hepatic sinusoidal obstruction syndrome after hematopoietic cell transplantation.‏
670 ‎‡a  Author's Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL)‏
670 ‎‡a  Author's Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System‏
670 ‎‡a  Author's Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia.‏
670 ‎‡a  Author's Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.‏
670 ‎‡a  Author's Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome.‏
670 ‎‡a  Author's Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML‏
670 ‎‡a  Author's Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome‏
670 ‎‡a  Author's Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry.‏
670 ‎‡a  Author's Prognostic significance of the FLT3 ITD mutation in patients with normal-karyotype acute myeloid leukemia in relapse‏
670 ‎‡a  Author's Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial‏
670 ‎‡a  Author's Significance of donor-derived isoagglutinins in ABO-Incompatible hematopoietic stem cell transplantation.‏
670 ‎‡a  Author's The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients‏
670 ‎‡a  Author's Two cases of myeloproliferative neoplasm with a concurrent JAK2‏
670 ‎‡a  Author's Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment‏
670 ‎‡a  Author's Two Rare Cases of Therapy-Related Acute Lymphoblastic Leukemia in Patients With Plasma Cell Myeloma‏
670 ‎‡a  Author's Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations‏
670 ‎‡a  Author's Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD)‏
909 ‎‡a  (orcid) 0000000270601675‏ ‎‡9  1‏
919 ‎‡a  significanceofdonorderivedisoagglutininsinaboincompatiblehematopoieticstemcelltransplantation‏ ‎‡A  Significance of donor-derived isoagglutinins in ABO-Incompatible hematopoietic stem cell transplantation.‏ ‎‡9  1‏
919 ‎‡a  prognosticimpactof100kitmutationinsystemicmastocytosisassociatedwithacutemyeloidleukaemiapatients‏ ‎‡A  The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients‏ ‎‡9  1‏
919 ‎‡a  2casesofmyeloproliferativeneoplasmwithaconcurrentjak2‏ ‎‡A  Two cases of myeloproliferative neoplasm with a concurrent JAK2‏ ‎‡9  1‏
919 ‎‡a  2casesofmyeloproliferativeneoplasmwithaconcurrentjak2v617fmutationandbcrabltranslocationwithoutchronicmyelogenousleukemiaphenotypeacquisitionduringhydroxyureatreatment‏ ‎‡A  Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment‏ ‎‡9  1‏
919 ‎‡a  validationoftreatmentoutcomesaccordingtorevisedseveritycriteriafromeuropeansocietyforbloodandmarrowtransplantationebmtforsinusoidalobstructionsyndromevenoocclusivediseasesosvod‏ ‎‡A  Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD)‏ ‎‡9  1‏
919 ‎‡a  useofazacitidineformyelodysplasticsyndromescontroversialissuesandpracticalrecommendations‏ ‎‡A  Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations‏ ‎‡9  1‏
919 ‎‡a  2rarecasesoftherapyrelatedacutelymphoblasticleukemiainpatientswithplasmacellmyeloma‏ ‎‡A  Two Rare Cases of Therapy-Related Acute Lymphoblastic Leukemia in Patients With Plasma Cell Myeloma‏ ‎‡9  1‏
919 ‎‡a  caseofdenovoaleukemicmastcellleukemiawithout100kitmutationsinexons8and17‏ ‎‡A  A case of de novo aleukemic mast cell leukemia without c-KIT mutations in exons 8 and 17.‏ ‎‡9  1‏
919 ‎‡a  caseofrefractorythrombocytopeniawith5qdeletionmyelodysplasticsyndromemimickingidiopathicthrombocytopenicpurpura‏ ‎‡A  A case of refractory thrombocytopenia with 5q deletion: myelodysplastic syndrome mimicking idiopathic thrombocytopenic purpura‏ ‎‡9  1‏
919 ‎‡a  novelhistonedeacetylaseinhibitorcg200745potentiatesanticancereffectofdocetaxelinprostatecancerviadecreasing11501andbcl40‏ ‎‡A  A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.‏ ‎‡9  1‏
919 ‎‡a  phase1b2bmulticenterstudyoforalpanobinostatplusazacitidineinadultswithmdscmmloramlwith30blasts‏ ‎‡A  A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.‏ ‎‡9  1‏
919 ‎‡a  phase2trialoffludarabinemelphalan100conditioningtherapyfollowedbyallogeneichematopoieticcelltransplantationforpatientswithlymphoma‏ ‎‡A  A Phase II Trial of Fludarabine/Melphalan 100 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation for Patients With Lymphoma‏ ‎‡9  1‏
919 ‎‡a  androgentherapyforpatientswithlowerriskmyelodysplasticsyndromeandsignificantcytopeniaaretrospectivestudy‏ ‎‡A  Androgen therapy for patients with lower-risk myelodysplastic syndrome and significant cytopenia: a retrospective study‏ ‎‡9  1‏
919 ‎‡a  biomarkersforhepaticsinusoidalobstructionsyndromeafterhematopoieticcelltransplantation‏ ‎‡A  Biomarkers for hepatic sinusoidal obstruction syndrome after hematopoietic cell transplantation.‏ ‎‡9  1‏
919 ‎‡a  busulfanetoposidecytarabineandmelphalanbueamasaconditioningregimenforautologousstemcelltransplantationinpatientswithnonhodgkinlymphomanhl‏ ‎‡A  Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL)‏ ‎‡9  1‏
919 ‎‡a  clinicaloutcomesofdecitabinetreatmentforpatientswithlowerriskmyelodysplasticsyndromeonthebasisoftheinternationalprognosticscoringsystem‏ ‎‡A  Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System‏ ‎‡9  1‏
919 ‎‡a  comparisonofanthracyclinesusedforinductionchemotherapyinpatientswithflt3itdmutatedacutemyeloidleukemia‏ ‎‡A  Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia.‏ ‎‡9  1‏
919 ‎‡a  establishmentandcharacterizationofhypomethylatingagentresistantcelllinesmolmaza1andmolmdec5‏ ‎‡A  Establishment and characterization of hypomethylating agent-resistant cell lines, MOLM/AZA-1 and MOLM/DEC-5.‏ ‎‡9  1‏
919 ‎‡a  expressionandprognosticsignificanceofmicrornasinkoreanpatientswithmyelodysplasticsyndrome‏ ‎‡A  Expression and prognostic significance of microRNAs in Korean patients with myelodysplastic syndrome.‏ ‎‡9  1‏
919 ‎‡a  gilteritiniborchemotherapyforrelapsedorrefractoryflt3mutatedaml‏ ‎‡A  Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML‏ ‎‡9  1‏
919 ‎‡a  lenalidomideasa2linetherapyafterfailureofhypomethylatingagentsinpatientswithmyelodysplasticsyndrome‏ ‎‡A  Lenalidomide as a second-line therapy after failure of hypomethylating agents in patients with myelodysplastic syndrome‏ ‎‡9  1‏
919 ‎‡a  predictivefactorsofmortalityinpopulationofpatientswithparoxysmalnocturnalhemoglobinuriapnhresultsfromakoreanpnhregistry‏ ‎‡A  Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry.‏ ‎‡9  1‏
919 ‎‡a  prognosticsignificanceoftheflt3itdmutationinpatientswithnormalkaryotypeacutemyeloidleukemiainrelapse‏ ‎‡A  Prognostic significance of the FLT3 ITD mutation in patients with normal-karyotype acute myeloid leukemia in relapse‏ ‎‡9  1‏
919 ‎‡a  safetyandtolerabilityofeltrombopagversusplacebofortreatmentofthrombocytopeniainpatientswithadvancedmyelodysplasticsyndromesoracutemyeloidleukaemiaamulticentrerandomisedplacebocontrolleddoubleblindphase12trial‏ ‎‡A  Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial‏ ‎‡9  1‏
996 ‎‡2  NTA|075007444‏
996 ‎‡2  ISNI|0000000377491859‏
996 ‎‡2  ISNI|0000000473781493‏
996 ‎‡2  BNF|12536294‏
996 ‎‡2  NUKAT|n 2006005522‏
996 ‎‡2  BIBSYS|90362303‏
996 ‎‡2  NII|DA04071328‏
996 ‎‡2  ISNI|0000000491681728‏
996 ‎‡2  ISNI|0000000480269973‏
996 ‎‡2  LC|n 84218241‏
996 ‎‡2  CAOONL|ncf11951655‏
996 ‎‡2  BNF|13183139‏
996 ‎‡2  SUDOC|031201830‏
996 ‎‡2  NTA|273435752‏
996 ‎‡2  ISNI|0000000464675904‏
996 ‎‡2  J9U|987007297153905171‏
996 ‎‡2  LC|n 2022182438‏
996 ‎‡2  ISNI|0000000513377445‏
996 ‎‡2  BNC|981058525074806706‏
996 ‎‡2  ISNI|000000049230879X‏
996 ‎‡2  ISNI|0000000019768168‏
996 ‎‡2  PLWABN|9810690524305606‏
996 ‎‡2  CAOONL|ncf10882333‏
996 ‎‡2  ISNI|0000000467872778‏
996 ‎‡2  DNB|120816679‏
996 ‎‡2  LC|n 2018015698‏
996 ‎‡2  ISNI|0000000074783088‏
996 ‎‡2  LC|no2006042521‏
996 ‎‡2  ISNI|0000000390574640‏
996 ‎‡2  LC|no2012052273‏
996 ‎‡2  ISNI|0000000492108106‏
996 ‎‡2  ISNI|0000000504764523‏
996 ‎‡2  ISNI|0000000491719167‏
996 ‎‡2  ISNI|0000000049390434‏
996 ‎‡2  ISNI|0000000066543084‏
996 ‎‡2  SUDOC|243280955‏
996 ‎‡2  CAOONL|ncf10309384‏
996 ‎‡2  NII|DA15036817‏
996 ‎‡2  ISNI|0000000391154576‏
996 ‎‡2  ISNI|0000000512340456‏
996 ‎‡2  J9U|987007376997505171‏
996 ‎‡2  ISNI|0000000463272492‏
996 ‎‡2  ISNI|000000050511213X‏
996 ‎‡2  NTA|260514004‏
996 ‎‡2  ISNI|000000008333839X‏
996 ‎‡2  J9U|987007277660405171‏
996 ‎‡2  ISNI|0000000081314319‏
996 ‎‡2  ISNI|0000000026536074‏
996 ‎‡2  ISNI|0000000110778711‏
996 ‎‡2  ISNI|0000000502791587‏
996 ‎‡2  BIBSYS|90663396‏
996 ‎‡2  ISNI|0000000505290403‏
996 ‎‡2  ISNI|0000000492097507‏
996 ‎‡2  SUDOC|268658633‏
996 ‎‡2  ISNI|0000000505843311‏
996 ‎‡2  LC|no2018041217‏
996 ‎‡2  ISNI|0000000504501678‏
996 ‎‡2  ISNI|000000048027000X‏
996 ‎‡2  CAOONL|ncf10126093‏
996 ‎‡2  NII|DA19868607‏
996 ‎‡2  SUDOC|147906083‏
996 ‎‡2  LC|no 95023008‏
996 ‎‡2  ISNI|0000000494054703‏
996 ‎‡2  DNB|1056135166‏
996 ‎‡2  SUDOC|243404603‏
996 ‎‡2  CAOONL|ncf10045051‏
996 ‎‡2  SUDOC|11100005X‏
996 ‎‡2  ISNI|0000000492378253‏
996 ‎‡2  ISNI|0000000503807149‏
996 ‎‡2  NUKAT|n 2020201747‏
996 ‎‡2  BIBSYS|90066988‏
996 ‎‡2  ISNI|0000000473671382‏
996 ‎‡2  ISNI|0000000475277899‏
996 ‎‡2  ISNI|0000000505600977‏
996 ‎‡2  DNB|1178565823‏
996 ‎‡2  CAOONL|ncf10119647‏
996 ‎‡2  DNB|1192313119‏
996 ‎‡2  DNB|170076903‏
996 ‎‡2  SUDOC|274011484‏
996 ‎‡2  ISNI|0000000479252963‏
996 ‎‡2  NUKAT|n 01108152‏
996 ‎‡2  SUDOC|276313186‏
996 ‎‡2  ISNI|0000000478596051‏
996 ‎‡2  ISNI|0000000463407270‏
996 ‎‡2  LC|no2009006927‏
996 ‎‡2  BIBSYS|15014226‏
996 ‎‡2  LC|n 80102639‏
996 ‎‡2  SUDOC|243288700‏
996 ‎‡2  DNB|127933816‏
996 ‎‡2  ISNI|0000000464822708‏
996 ‎‡2  NTA|129747440‏
996 ‎‡2  NTA|070264252‏
996 ‎‡2  ISNI|0000000467874685‏
996 ‎‡2  ISNI|0000000043258205‏
996 ‎‡2  LC|n 90687677‏
996 ‎‡2  LC|no2006089357‏
996 ‎‡2  ISNI|0000000493004202‏
996 ‎‡2  DNB|1089401760‏
996 ‎‡2  ISNI|0000000474239022‏
996 ‎‡2  ISNI|0000000494055132‏
996 ‎‡2  ISNI|0000000492134259‏
996 ‎‡2  ISNI|0000000480115771‏
996 ‎‡2  ISNI|0000000362123316‏
996 ‎‡2  LC|nr2004031217‏
996 ‎‡2  ISNI|0000000505107533‏
996 ‎‡2  LC|n 94061273‏
996 ‎‡2  PLWABN|9810571477105606‏
996 ‎‡2  ISNI|0000000473970104‏
996 ‎‡2  ISNI|000000051316495X‏
996 ‎‡2  NUKAT|n 2005036040‏
996 ‎‡2  LC|n 88614502‏
996 ‎‡2  BIBSYS|90276147‏
996 ‎‡2  ISNI|0000000467848102‏
996 ‎‡2  J9U|987008757075405171‏
996 ‎‡2  ISNI|0000000505969563‏
996 ‎‡2  ISNI|0000000494054738‏
996 ‎‡2  ISNI|0000000505178825‏
996 ‎‡2  ISNI|0000000473763949‏
996 ‎‡2  BIBSYS|12007431‏
996 ‎‡2  ISNI|0000000483483414‏
996 ‎‡2  NTA|326886435‏
996 ‎‡2  ISNI|0000000473438492‏
996 ‎‡2  NTA|141541164‏
996 ‎‡2  ISNI|0000000491938298‏
996 ‎‡2  PLWABN|9810570744005606‏
996 ‎‡2  DNB|17295004X‏
996 ‎‡2  DNB|128876557‏
996 ‎‡2  ISNI|0000000484956500‏
996 ‎‡2  LC|n 86858616‏
996 ‎‡2  ISNI|0000000023551287‏
996 ‎‡2  ISNI|0000000483866749‏
996 ‎‡2  DNB|1213491762‏
996 ‎‡2  ISNI|0000000468417603‏
996 ‎‡2  SUDOC|280101848‏
996 ‎‡2  PTBNP|266135‏
996 ‎‡2  SUDOC|057303525‏
996 ‎‡2  SUDOC|093600542‏
996 ‎‡2  LIH|LNB:B,L_f_;=BV‏
996 ‎‡2  DNB|107109467X‏
996 ‎‡2  NTA|273408070‏
996 ‎‡2  ISNI|0000000513383335‏
996 ‎‡2  ISNI|0000000395253328‏
996 ‎‡2  ISNI|0000000494047028‏
996 ‎‡2  ISNI|0000000427747518‏
996 ‎‡2  PLWABN|9810697243705606‏
996 ‎‡2  NDL|001109589‏
996 ‎‡2  NII|DA04643986‏
996 ‎‡2  ISNI|0000000111299026‏
996 ‎‡2  PLWABN|9810558831005606‏
996 ‎‡2  LC|n 80094424‏
996 ‎‡2  ISNI|0000000491681832‏
996 ‎‡2  RERO|A003507220‏
996 ‎‡2  RERO|A003507221‏
996 ‎‡2  SUDOC|172544556‏
996 ‎‡2  ISNI|0000000479092429‏
996 ‎‡2  LC|n 99031302‏
996 ‎‡2  LC|no2021043427‏
996 ‎‡2  ISNI|0000000465110390‏
996 ‎‡2  LC|no2001069856‏
996 ‎‡2  ISNI|0000000468730464‏
996 ‎‡2  B2Q|0000122847‏
996 ‎‡2  BIBSYS|7058374‏
996 ‎‡2  ISNI|0000000463565658‏
996 ‎‡2  LC|n 84130560‏
996 ‎‡2  NII|DA13800032‏
996 ‎‡2  DBC|87097968620589‏
996 ‎‡2  ISNI|0000000483506428‏
996 ‎‡2  BIBSYS|90150658‏
996 ‎‡2  NII|DA04560947‏
996 ‎‡2  ISNI|0000000491601273‏
996 ‎‡2  BIBSYS|90233075‏
996 ‎‡2  LC|n 88648608‏
996 ‎‡2  NTA|06824584X‏
996 ‎‡2  PLWABN|9811239848005606‏
996 ‎‡2  ISNI|0000000029603148‏
996 ‎‡2  LC|n 85132752‏
996 ‎‡2  CAOONL|ncf11734251‏
996 ‎‡2  RERO|A005926369‏
996 ‎‡2  LC|n 85035406‏
996 ‎‡2  PLWABN|9810597976005606‏
996 ‎‡2  LC|n 2011061792‏
996 ‎‡2  ISNI|0000000074639481‏
996 ‎‡2  J9U|987007357685805171‏
996 ‎‡2  CAOONL|ncf10012620‏
996 ‎‡2  ISNI|0000000409372636‏
996 ‎‡2  LC|nb2019002248‏
996 ‎‡2  ISNI|0000000053174371‏
996 ‎‡2  ISNI|0000000084870580‏
996 ‎‡2  ISNI|0000000492322938‏
996 ‎‡2  RERO|A003507219‏
996 ‎‡2  SUDOC|184278481‏
996 ‎‡2  NTA|345817540‏
996 ‎‡2  ISNI|0000000513219965‏
996 ‎‡2  ISNI|0000000492870424‏
996 ‎‡2  LC|no2010160834‏
996 ‎‡2  ISNI|000000046778863X‏
996 ‎‡2  LC|no 00086598‏
996 ‎‡2  ISNI|0000000478879131‏
996 ‎‡2  ISNI|0000000494054826‏
996 ‎‡2  PLWABN|9810633846105606‏
996 ‎‡2  ISNI|0000000073449184‏
996 ‎‡2  ISNI|0000000028266450‏
996 ‎‡2  ISNI|0000000505968042‏
996 ‎‡2  ISNI|0000000503881605‏
996 ‎‡2  DNB|1119110548‏
996 ‎‡2  ISNI|0000000114633827‏
996 ‎‡2  ISNI|0000000467633531‏
996 ‎‡2  RERO|A027421481‏
996 ‎‡2  NUKAT|n 2016173616‏
996 ‎‡2  BIBSYS|98029465‏
996 ‎‡2  ISNI|0000000494021186‏
996 ‎‡2  BNE|XX1104116‏
996 ‎‡2  BIBSYS|97034786‏
996 ‎‡2  ISNI|0000000477768691‏
996 ‎‡2  NUKAT|n 2018166886‏
996 ‎‡2  ISNI|0000000476670107‏
996 ‎‡2  ISNI|0000000513753869‏
996 ‎‡2  N6I|vtls002001515‏
996 ‎‡2  BIBSYS|1523345892089‏
996 ‎‡2  SUDOC|127480870‏
996 ‎‡2  ISNI|0000000019602838‏
996 ‎‡2  J9U|987007439983805171‏
996 ‎‡2  DNB|172236592‏
996 ‎‡2  ISNI|0000000513621321‏
996 ‎‡2  ISNI|0000000504572820‏
996 ‎‡2  NTA|142053589‏
996 ‎‡2  DNB|1103614118‏
996 ‎‡2  ISNI|0000000473764335‏
996 ‎‡2  ISNI|0000000465089499‏
996 ‎‡2  ISNI|0000000063353728‏
996 ‎‡2  LC|nb2015000348‏
996 ‎‡2  BIBSYS|90386639‏
996 ‎‡2  BNF|16643420‏
996 ‎‡2  ISNI|000000045933737X‏
996 ‎‡2  ISNI|0000000491798045‏
996 ‎‡2  ISNI|0000000473361384‏
996 ‎‡2  ISNI|0000000468019963‏
996 ‎‡2  LC|nr 95026164‏
996 ‎‡2  DNB|132065118‏
996 ‎‡2  ISNI|0000000478596588‏
996 ‎‡2  ISNI|0000000479176972‏
996 ‎‡2  J9U|987007411854505171‏
996 ‎‡2  ISNI|0000000043189481‏
996 ‎‡2  ISNI|000000047336055X‏
996 ‎‡2  JPG|500009153‏
996 ‎‡2  ISNI|0000000480057014‏
996 ‎‡2  ISNI|0000000472526917‏
996 ‎‡2  LC|n 82062612‏
996 ‎‡2  ISNI|0000000463564380‏
996 ‎‡2  NII|DA15130804‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏